126301-19-7

Upstream product

• 117049-14-6 tert-butyl N-[(1S)-2-hydroxy-1-phenylethyl]carbamate 
• 124-63-0 methanesulfonyl chloride 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3182-95-4 L-Phenylalaninol 
• 63-91-2 L-phenylalanine 
• 66605-57-0 (S)-N-tert-butoxycarbonyl-2-amino-3-phenylpropanol 
• 7143-01-3 Methanesulfonic anhydride 
• 5267-64-1 (R)-2-amino-3-phenylpropanol 
• 18942-49-9 Boc-D-Phe-OH 
• 106454-69-7 N-tert-butoxycarbonyl-D-Phenylalaninol 
• 51987-73-6 (S)-2-tert-butoxycarbonylamino-3-phenyl-propionic acid methyl ester 
• 19901-50-9 methyl (2R)-2-(t-butoxycarbonylamino)-3-phenylpropionate 
• 67729-36-6 Boc-Phe-O-COO-isoBu 

Downstream Products

• 155392-44-2 (S)-(-)-N-(tert-butoxycarbonyl)-1-(methylthio)-3-phenyl-2-propylamine 
• 109687-70-9 tert-butyl (S)-(1-phenyl-3-(phenylthio)propan-2-yl)carbamate 
• 126301-23-3 (S)-2-amino-3-phenylpropyl methanesulphonate hydrochloride 
• 167421-92-3 tert-butyl (S)-N-[1-(ethylsulfanylmethyl)-2-phenylethyl]carbamate 
• 185384-15-0 (S)-tert-butyl (1-bromo-3-phenylpropan-2-yl)carbamate 
• 920760-36-7 (2-phenyl-1-p-tolylsulfanylmethyl-ethyl)-carbamic acid tert-butyl ester 
• 146476-36-0 tert-butyl (S)-(1-(diphenylphosphanyl)-3-phenylpropan-2-yl)carbamate 
• 156358-27-9 (S)-1-phenyl-3-(phenylthio)propan-2-amine 
• 340161-32-2 (S)-2-amino-1-(ethylsulfanyl)-3-phenylpropane 
• 190589-82-3 3,5-Bis-((S)-2-tert-butoxycarbonylamino-3-phenyl-propoxy)-benzoic acid 
• 190589-80-1 3,5-Bis-((S)-2-tert-butoxycarbonylamino-3-phenyl-propoxy)-benzoic acid methyl ester 
• 145641-39-0 ((S)-1-Chlorosulfinylmethyl-2-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 145641-42-5 N-phenylalanine methyl ester 
• 145641-43-6 N-phenylalanine methyl ester 

Relevant academic research and scientific papers

USP30 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.

PEPTIDE-OLIGOUREA HYBRID COMPOUNDS

The present description relates to peptidomimetic foldamers, and their synthesis. In particular, the description provides peptide-amino urea hybrid peptidomimetic foldamers comprising an alpha amino acid peptide portion and an oligourea portion.

Development of Chiral Organosuperbase Catalysts Consisting of Two Different Organobase Functionalities

In the field of chiral Br?nsted base catalysis, a new generation of chiral catalysts has been highly anticipated to overcome the intrinsic limitation of pronucleophiles that are applicable to the enantioselective reactions. Herein, we reveal conceptually new chiral Br?nsted base catalysts consisting of two different organobase functionalities, one of which functions as an organosuperbase and the other as the substrate recognition site. Their prominent activity, which stems from the distinctive cooperative function by the two organobases in a single catalyst molecule, was demonstrated in the unprecedented enantioselective direct Mannich-type reaction of α-phenylthioacetate as a less acidic pronucleophile. The present achievement would provide a new guiding principle for the design and development of chiral Br?nsted base catalysts and significantly broaden the utility of Br?nsted base catalysis in asymmetric organic synthesis.

Asymmetric kinetic resolution of sulfides for the construction of unsymmetric sulfides and chiral 3,3-disubstituted oxindoles

A range of 3,3-disubstituted oxindoles accessed using para-quinone methides derived from isatins with thiols were used for the formation of unsymmetrical disulfides, and 3,3-disubstituted oxindoles with a chiral quaternary carbon center and unsymmetric di

Synthesis and evaluation of chirally defined side chain variants of 7-chloro-4-aminoquinoline to overcome drug resistance in malaria chemotherapy

A novel 4-aminoquinoline derivative [(S)-7-chloro-N-(4-methyl-1-(4-methyl-piperazin-1-yl)pentan-2-yl)-quinolin-4-amine triphosphate] exhibiting curative activity against chloroquine-resistant malaria parasites has been identified for preclinical development as a blood schizonticidal agent. The lead molecule selected after detailed structure-activity relationship (SAR) studies has good solid-state properties and promising activity against in vitro and in vivo experimental malaria models. The in vitro absorption, distribution, metabolism, and excretion (ADME) parameters indicate a favorable drug-like profile.

Synthesis and antimalarial activity of new 4-aminoquinolines active against drug resistant strains

In the present study we have synthesized a new class of 4-aminoquinoline derivatives via replacement of the diethylamine functionality of chloroquine (CQ) with acyclic and/or cyclic amine groups containing basic tertiary terminal nitrogen and bioevaluated them for antimalarial activity against Plasmodium falciparum in vitro (CQ-sensitive strain-3D7 & CQ-resistant strain-K1) and Plasmodium yoelii in vivo (N-67 strain). Among the series, thirteen compounds showed superior antimalarial activity against K1 strain as compared to CQ. In addition, all these analogs showed 100% suppression of parasitaemia on day 4 in the in vivo mouse model against N-67 strain when administered orally. Further, biophysical studies suggest that these compounds act on the heme polymerization target.

N a aminopeptidase inhibitor and its preparation method and application

The invention discloses an aminopeptidase N inhibitor which has a chemical name of 2-((S)-3-(3-((S)-2-amino-3-phenylpropyl)urea)-2,6-dioxopiperidine-1-yl)-N-hydroxyacetamide hydrochloride and is a compound with a structural formula (I) described in the sp

HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS

Disclosed are compounds of Formula (I) or salts thereof, wherein HET is a heteroaryl selected from pyrrolo[2,3 b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY

PROBLEM TO BE SOLVED: To provide 6-O-substituted ketolides with antibacterial activity, having acid stability and enhanced activity toward gram negative bacteria and macrolide resistant gram positive bacteria. SOLUTION: This invention provides 6-O-substituted erythromycin ketolide derivatives such as formula (II) and compositions comprising the compounds. [Y and Z together form a group X; X is ketone, hydroxyimino or the like; or, one of Y and Z is H and the other is hydrogen, hydroxy or the like; Ra is H, hydroxy; Rc is H or a hydroxy protective group; R is a substituted methyl group]. COPYRIGHT: (C)2015,JPOandINPIT

METHODS FOR INHIBITING DRUG DEGRADATION

Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters